Nomad Power Solutions, Inc. NMAD
Nomad Power Solutions, Inc. (Nasdaq: NMAD) is an oncology life-science company. Its next catalyst on record is LB-100 + dostarlimab: Trial completion (2028).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: LB-100 + dostarlimab — Trial completion (2028). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LB-100 + dostarlimab (MD Anderson/Northwestern, GSK-supported) | ovarian clear cell carcinoma | small molecule | Phase 1 |
| LB-100 + atezolizumab (NKI, Roche-supported) | metastatic MSS colorectal cancer (Phase 1b) | small molecule | Phase 1 |
| LB-100 + doxorubicin (Spain, Phase 1b/randomized Phase 2) | advanced soft tissue sarcoma | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.